BI
ACHN

BVF Inc’s Achillion Pharmaceuticals ACHN Stock Holding History

BVF Inc’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,608,433
Closed -$4.63M – 48
2017
Q4 		$4.63M Buy
+1,608,433
New +$5.84M 0.56% 35
2017
Q3 		– Sell
-3,490,077
Closed -$16M – 39
2017
Q2 		$16M Buy
3,490,077
+204,677
+6% +$823K 2.49% 13
2017
Q1 		$13.8M Buy
3,285,400
+862,100
+36% +$3.58M 2.35% 14
2016
Q4 		$10M Buy
+2,423,300
New +$12.9M 2.01% 14

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BVF Inc's ACHN Position: Q1 2018 in Review

BVF Inc sold out of Achillion Pharmaceuticals (ACHN) in Q1 2018, closing a stake of 1,608,433 shares — an estimated $4.63M sold.

BVF Inc first reported a position in ACHN in Q4 2016 and held it in 4 quarters. The position peaked at $16M in Q2 2017. 127 funds tracked by Wall St. Rank hold ACHN as of Q1 2018.

  • BVF Inc reported no remaining Achillion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • BVF Inc sold 1,608,433 Achillion Pharmaceuticals shares in Q1 2018, an estimated $4.63M.
  • BVF Inc first reported a position in Achillion Pharmaceuticals in Q4 2016 and held it in 4 quarters.
  • BVF Inc's Achillion Pharmaceuticals position peaked at $16M in Q2 2017.
  • 127 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2018.

Based on BVF Inc's 13F filing for Q1 2018, filed 7 May 2018.